Pfizer is busy downsizing from health-care conglomerate to a focused pharmaceutical company. It sold off its nutrition business to Nestle for $12 billion and spun out 20% of its animal health division into a new company, Zoetis, for more than $2 billion.
The big pharma announced today that it plans to get rid of its remaining 80% position in the animal health company on June 19 and is even willing to swap out its Zoetis shares on sale!
In this video, health-care analyst David Williamson discusses what these events mean for investors in Pfizer and Zoetis and gives his take on the company's breakup.
